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One of the major signaling pathways by which extra-
cellular signals induce cell proliferation and differenti-
ation involves the activation of extracellular signal-reg-
ulated kinases (ERKs). Because calmodulin is essential
for quiescent cells to enter cell cycle, the role of calmod-
ulin on ERK2 activation was studied in cultured fibro-
blasts. Serum, phorbol esters, or active Ras induced
ERK2 activation in NIH 3T3 fibroblasts. This activation
was not inhibited by calmodulin blockade. Surprisingly,
inhibition of calmodulin prior to fetal bovine serum ad-
dition prolonged activation of ERK2. Furthermore, in-
activation of calmodulin in serum-starved cells induced
ERK2 phosphorylation that was dependent on MAP ki-
nase kinase (MEK). Inactivation of calmodulin in serum-
starved cells also induced activation of Ras, Raf, and
MEK. On the contrary, tyrosine phosphorylation of ty-
rosine kinase receptors was not observed. These results
indicate that calmodulin inhibits ERK2 activation path-
way at the level of Ras. Calmodulin inhibition induced
overexpression of p21cip1 which was dependent on MEK
activity. We propose that inhibition of Ras by calmodu-
lin prevents the activation of ERK2 at low serum con-
centration. Thus, entering into the cell cycle after serum
addition would imply the overcoming of the inhibitory
effect of calmodulin and consequently ERK2 activation.
Furthermore, down-regulation of Ras by calmodulin
may be also important to determine the duration of
ERK2 activation and to prevent a high p21cip1 expres-
sion that would lead to an inhibition of cell proliferation.
Cells have evolved signal transduction pathways that allow
them to respond to extracellular signals. Those signaling path-
ways will lead to the regulation of effector proteins that will
finally cause cell proliferation or differentiation.
One of the major signal transduction pathways results in the
activation of a class of intracellular protein serine/threonine
kinases termed extracellular signal-regulated kinases (ERKs),1
also known as mitogen-activated protein kinases (MAPKs) (1).
Two highly related mammalian ERKs, ERK1 (p44MAPK) and
ERK2 (p42MAPK) are activated in response to growth factors
and hormones (2, 3). Once activated, those kinases are able to
phosphorylate and activate numerous cytoplasmic proteins in-
cluding p90rsk (S6 ribosomal protein kinase) (4), phospholipase
A2 (5), and EGF receptor (6). After stimulation, ERKs translo-
cate into the nucleus (7) where they activate a number of
transcription factors such as Elk1 (8, 9), c-Ets1, and c-Ets2 (10),
thus altering the pattern of gene expression (11).
ERKs are activated by a dual phosphorylation on threonine
and tyrosine residues. Their specific activators, called MAP
kinase kinases (MAPKK) or MEK, constitute a new family of
dual-specific threonine/tyrosine kinases (12). MEK1 and MEK2
are the kinases known to activate ERK1 and ERK2. MEK1 and
MEK2 are in turn activated by an upstream MAP kinase ki-
nase kinase, which has been identified as the product of the
proto-oncogene raf-1 (13). Raf-1 seems to integrate different
signals that will lead to ERK activation. Its activation is com-
plex and not completely well understood, with Ras activation
being an essential element in the pathway. Active Ras targets
Raf-1 to the cell membrane and becomes attached to it by an
unknown mechanism (14). However, recruitment of Raf to the
membrane by binding to Ras cannot account for full activation
of Raf (15). Ras GTPases exist in two conformations, an inac-
tive GDP-bound form and an active GTP-bound state. The
cyclic interconversion of Ras is regulated by the activity of the
guanidine exchange factors (GEFs), which allow the replace-
ment of Ras-bound GDP by GTP, and the Ras-GTPase activat-
ing proteins (GAPs), which activate the intrinsic GTPase ac-
tivity of Ras that converts GTP back to GDP (16). Activation of
Ras by tyrosine kinase receptors involves recruitment of SOS,
a guanidine exchange factor to the membrane (2). Other GEFs
non-activated by tyrosine kinase receptors that activate Ras
have been identified in mammalian cells such as Ras-GRF/
CDC25Mm (17).
Activation of the ERK pathway is transient, and it has been
argued that it is the duration of ERKs activation that deter-
mines whether a stimulus elicits proliferation or differentiation
(18, 19, 20). In cells activated to proliferate, Raf is associated to
the membrane only for 5 min, and its activity decreases to basal
levels 15 min after growth factor addition in cultured fibro-
blasts (21). ERKs activity after mitogenic stimuli shows a ini-
tial peak at 5–10 min followed by a sustained phase of lower
activity of 4 h (22). However, a more prolonged or a high
intensity activation of the MAPK pathway induces growth ar-
rest of the cells mediated by the cell cycle inhibitor p21cip1 (20,
23, 24). Whereas much attention has focused on the mecha-
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nisms leading to ERK phosphorylation by growth factors and
oncoproteins, few studies have turned to the question of how
the pathway is down-regulated. Several constitutive and induc-
ible ERK phosphatases responsible for its down-regulation
have been described (25), including Pyst1 (26), MKP1, 2 (27,
28), and PAC1 (29). Expression of MKP1 has been shown to be
ERK- and Ca21-dependent (30). Less is known about the down-
regulation of the pathway upstream of ERK. In some cells,
ERK mediates the phosphorylation of SOS to terminate Ras-
dependent activation of ERK (31).
Ca21 and calmodulin (CaM) are known to act as second
messengers in signal transduction pathways and to regulate
cell proliferation (32–35). Through the action of CaM-binding-
proteins like CaM-dependent kinases II and IV, calcineurin,
hnRNP A2, hnRNP C, and others, they regulate a great variety
of cellular processes, such as gene expression, protein transla-
tion, and protein phosphorylation (36). By using expression
vectors capable of inducibly synthesizing CaM sense or anti-
sense mRNAs, it has been shown that progression through G1
and mitosis exit is sensitive to changes in the intracellular
concentration of CaM (37). Furthermore, the addition of spe-
cific anti-CaM drugs to cell cultures inhibits reentry of growth-
arrested cells into the cell cycle (G0/G1 transition), the progres-
sion into and through the S phase and the entry and exit from
mitosis (35, 38–44). During G1, CaM is essential to activate
cdk4 and phosphorylate pRb (44, 45). Moreover CaM partici-
pates in the activation of cdc2 during mitosis entry (33) and in
its inactivation at the metaphase/anaphase transition (46). De-
spite the evidence indicating that CaM plays a role in cell cycle
entry from quiescence (G0/G1 transition), not much is known
about the CaM-dependent steps essential for this transition.
CaM has been shown to play a role in the activation of the
MAPK signaling pathway (47–51). For example, the Ras-GRF
exchange factor of cortical neurons is a CaM-binding-proteins,
and a Ca21 influx in these cells is able to activate Ras and
ERKs (47). In other cellular types, CaM-dependent kinases
have been involved in the MAPK activation pathway (50–51).
We have analyzed here the involvement of CaM in the ERK
signaling pathway in cell-cultured fibroblast. Surprisingly, re-
sults show that CaM is not essential for the activation of the
ERK pathway but for its inactivation. This down-regulation of
the pathway is due at least in part to an inhibitory effect of
CaM on Ras activation. Furthermore, activation of ERK2 by
CaM inhibition induces an increase in p21cip1 expression to-
gether with a cell cycle arrest.
EXPERIMENTAL PROCEDURES
Cell Culture—NIH 3T3 cells (ATCC) or NIH 3T3 cells constitutively
expressing active mutant N-Ras (lys61) under a CMV promoter (NIH
3T3RasLys61) (gift of Dr. T. Thompson, Barcelona) or normal rat kid-
ney cells (NRK) were made quiescent by culturing them in Dulbecco’s
minimum essential medium with 0.5% fetal bovine serum (FBS) during
2 days. 10% FBS, 100 mM TPA, 25 ng/ml EGF, 15 mg/ml W13, 15 mg/ml
W12, 5 mM KN93, or 2 mg/ml cyclosporin A were added directly to the
media, and for the time indicated in the results.
Gel Electrophoresis and Immunoblotting—Cells were lysed in a
buffer containing 2% SDS, and 67 mM Tris-HCl, pH 6.8. The same
amount of protein of each extract was electrophoresed in SDS-10%
PAGE gels essentially as described by Laemmli (52). After electrophore-
sis, the proteins were transferred to Immobilon-P strips for 2 h at 60 V.
The sheets were preincubated in TBS (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl), 0.05% Tween-20, and 5% BSA for 1 h at room temperature and
then incubated for 1 h at room temperature in TBS, 0.05% Tween 20,
1% BSA, and 0.5% defatted milk powder containing antibodies against:
ERK1 and ERK2 (03–6600 Zymed Laboratories Inc., 1:500 dilution),
phospho-ERK1 and ERK2 (No. 9101S, New England Biolabs, 1:500
dilution), phospho-MEK (No. 9121S, New England Biolabs, 1:500 dilu-
tion), c-Raf-1 (R19120 Transduction Lab., 1:500 dilution), phospho-Tyr
(PY20, Transduction Lab., 1:750 dilution). After washing in TBS, 0.05%
Tween-20 (three times, 10 min each), the sheets were incubated with
either a peroxidase-coupled secondary antibody (1:1000 dilution) (Bio-
Rad) or an alkaline phosphatase-coupled secondary antibody (1:10000)
(Promega) for 1 h at room temperature. After incubation, the sheets
were washed twice in TBS, 0.05% Tween 20, and once in TBS. The
reaction was visualized by ECL (Amersham Pharmacia Biotech) or with
BCIP/NBT (Promega). Control of protein loading and transfer was done
by stripping the gels and re-blotting them with anti-ERK1 and -ERK2
antibodies.
Raf Immunoprecipitation and Kinase Assay—Immunoprecipitations
were performed as described by Morrison (53). Cells (5–10 3 107) were
lysed in 1 ml of radioimmune precipitation buffer (20 mM Tris-HCl, pH
8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.1% SDS, 0.5%
sodium deoxycholate, 2 mM EDTA) containing 1 mM PMSF, 1 mM
aprotinin, 20 mM leupeptin, and 5 mM sodium vanadate. To immuno-
precipitate Raf-1 from cells lysates, 2.5 mg of anti-Raf-1 (R19120, Trans-
duction Lab) or 2.5 mg of a nonrelated monoclonal antibody were first
prebound to 20 ml of protein G-Sepharose beads (Sigma) in 1 ml of
radioimmune precipitation buffer for 1 h at room temperature. The
anti-Raf-coated beads were washed twice with radioimmune precipita-
tion buffer. Then, 500 mg of protein from the lysates were added and
incubated for 2 h at 4 °C. The immunoprecipitated complexes were
washed three times with 1 ml of cold Nonidet P-40 lysis buffer (20 mM
Tris-HCl, pH 8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM
EDTA) containing 1 mM PMSF, 1 mM aprotinin, 20 mM leupeptin, and 5
mM sodium vanadate, resuspended, and incubated for 20 min at 25 °C
in 40 ml of kinase buffer (30 mM HEPES-Na, pH 7.4, 7 mM MnCl2, 5 mM
MgCl2, 100 mM NaCl, 1 mM dithiothreitol, 15 mM ATP) plus 20 mCi of
[g-32P]ATP(3000 Ci/mmol; Amersham Pharmacia Biotech) and 40
mg/ml pGST-MEK inactive fusion protein. Then, the samples were
electrophoresed on SDS-polyacrylamide gels, and the gels were stained
with Coomassie Blue, dried, and exposed to x-ray films at 280 °C.
Immunocytochemistry—Quiescent cells were grown on glass cover-
slips. To detect ERK1 and ERK2 cells were fixed in 4% paraformalde-
hyde/phosphate-buffered saline (PBS) for 10 min at room temperature
and permeabilized at 220 °C for 10 min with methanol. After washing
three times with PBS, the nonspecific sites were subsequently blocked
with sheep serum in PBS (1:5) for 30 min at room temperature. Cells
were then incubated 1 h at 37 °C, with the specific polyclonal antibodies
anti-ERK1 and ERK2 (No. 06–182; Upstate Biotechnology) in 1% BSA/
PBS (1:200). Coverslips were then washed three times (5 min each) in
PBS and incubated for 45 min at 37 °C with fluorescein-conjugated
anti-rabbit antibody (dilution 1:50, Boehringer) in 1% BSA/PBS. After
two washes in PBS, coverslips were mounted on glass slides with Mowiol
(Calbiochem).
Measurement of Ras Activation—The capacity of Ras-GTP to bind to
RBD (Ras-binding domain of Raf-1) was used to analyze the amount of
active Ras (54, 55). Cells were lysed in the culture dish with 25 mM
Tris-HCl, pH 7.5, 5 mM EGTA, 150 mM NaCl, 5 mM MgCl2, 1% Triton
X-100, 1% N-octyl glucoside, 1 mM PMSF, 1 mM aprotinin, and 20 mM
Leupeptin. Cleared (10,000 3 g) lysate (1 mg) was incubated with 30 mg
of GST-RBD bound to glutathione-Sepharose beads for 2 h at 4 °C.
Beads were washed four times with the lysis buffer. Bound proteins
were solubilized by the addition of 30 ml of Laemmli loading buffer and
run on 12.5% SDS-PAGE gels. Proteins were then transferred and
immunoblotted as described above using pan-Ras monoclonal antibody
(Oncogene Sciences OP40, 1:100 dilution).
RESULTS
Effect of CaM Inhibition on ERK2 Activation—Stimulation of
serum-starved NIH 3T3 fibroblast by 10% FBS, or 100 mM TPA
for 10 min, resulted in an activation of ERK2, as demonstrated
by the increase in ERK2 tyrosine phosphorylation analyzed by
Western blotting using antiphosphotyrosine antibodies (Fig.
1A) or phospho-specific anti-ERK1 and -ERK2 antibodies (data
not shown). To analyze if CaM was essential for the signaling
pathways leading to ERK2 phosphorylation, quiescent cells
were pretreated with the anti-CaM drug W13 (15 mg/ml) for 20
min prior to stimulation with FBS or TPA. W13 has been
extensively used to inhibit CaM in cell cultures, and it is known
to be highly specific at the doses used in this work (40, 42, 56,
57). W12 was used as a control because it is a compound
chemically similar to W13 but with a much lower affinity for
CaM (40). As shown in Fig. 1A, W13-pretreatment did not have
any effect on the level of phosphorylated ERK2, determined by
Western blotting using antiphosphotyrosine (PY20) antibody
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(Fig. 1A). The same results were obtained using the antiphos-
pho-ERK2 specific antibodies (data not shown).
ERK2 phosphorylation was also induced at 0.5% FBS by
expression of activated N-Ras. Inhibition of CaM in NIH
3T3NRas(Lys61)-transformed cells by W13 treatment for 30
min did not have any effect on Ras-induced ERK2 phosphoryl-
ation (Fig. 1B). Thus, CaM is not essential for any of the
studied signaling pathways leading to ERK2 activation in NIH
3T3.
Effect of CaM Inhibition on ERK2 Down-regulation—Be-
cause the duration of ERKs activation is also important for cell
response, the effect of CaM inhibition on the timing of ERKs
phosphorylation was analyzed. In nontreated cells (data not
shown) or in cells preincubated with W12 (for 20 min prior to
10% FBS addition) (Fig. 2), ERK2 phosphorylation was high at
10 min, started to decrease at 30 min, and was slightly higher
than in unstimulated cells by 2 h after FBS addition. Surpris-
ingly, when cells where preincubated with W13, ERK2 phos-
phorylation still remained high 2 h after the stimulation (Fig.
2). Inhibition of CaM later in G1 (between 4 and 10 h after
serum addition), when ERK2 phosphorylation was already de-
creased, did not lead to a second activation of ERK2 (data not
shown). Thus, inhibition of CaM prolonged the phosphorylation
of ERK2, suggesting that CaM is involved in its down-regulation.
The effect of W13 on ERK2 phosphorylation in serum-
starved cells was also analyzed. When serum-starved cells
(0.5% FBS) were incubated with W13 for 30 min, an increase in
ERK2 phosphorylation was observed. This increase was similar
to that produced by addition of 10% FBS and was not observed
with W12 (Fig. 3A). This effect was not mediated by CaM-de-
pendent kinase II or calcineurin because treatment of serum-
starved cells with KN93, an inhibitor of CaM-dependent-kinase
II, or cyclosporin A, an inhibitor of calcineurin, did not induce
ERK2 phosphorylation (Fig. 3A).
Cooperation between FBS addition and CaM inhibition to
induce ERK2 phosphorylation was analyzed in quiescent cells
that had been maintained for the last 10 h in the complete
absence of FBS. Cells were pre-treated with W12 or W13 for 20
min, and ERK2 phosphorylation was studied 10 min after
addition of increasing amounts of FBS. As shown in Fig. 3B,
W13 addition synergized with low concentrations of FBS to
induce ERK2 phosphorylation. Maximal increase in ERK2
phosphorylation induced by CaM inhibition was observed at
0.5% FBS. In agreement with the results in Fig. 1A, when the
amount of FBS added to the media was higher than 2%, no
additional increase in ERK2 phosphorylation was induced by
CaM inhibition (Fig. 3B). Similar results were obtained using
NRK cells (data not shown). These results suggest that CaM
inhibits any of the signaling pathways by which FBS activates
ERK2.
We also analyzed whether ERK2 phosphorylation induced by
CaM inhibition in serum-starved cells correlated with a nu-
clear accumulation of ERKs. As shown in Fig. 4, after 2 days of
serum starvation, ERK2 was localized in the cytoplasm. Treat-
ment with W13 for 30 min induced a translocation of ERK2 into
the nucleus similar to what occurred with 10% FBS incubation.
W13 treatment of serum-starved NIH 3T3 cells also induced an
increase in fos mRNA levels analyzed by Northern blotting
(data not shown).
Analysis of the Pathway Leading to ERK2 Activation by CaM
FIG. 1. Effect of W13 addition on ERK2 phosphorylation in-
duced by FBS, TPA, or Ras. A, ERK2 phosphorylation in serum- and
TPA-stimulated NIH 3T3 fibroblasts after pretreatment with the anti-
CaM drug W13. Quiescent NIH 3T3 cells (Q) were stimulated for 10 min
with 10% FBS or 100 mM TPA. In the indicated lanes, W12 or W13 (15
mg/ml) was added to the cultures 20 min prior to FBS or TPA addition.
B, quiescent NIH 3T3Nras(lys61) (Q) cells, expressing the constitu-
tively active N-ras (lys61) mutant, were treated for 30 min with W12 or
W13 (15 mg/ml). In panels A and B, cells were lysed and ERK2 phos-
phorylation analyzed by Western blotting using the antiphosphoty-
rosine (PY20) antibody as indicated under “Experimental Procedures.”
P-ERK2 corresponds to a band of 42 kDa that comigrates with ERK2
using anti-ERK1 and ERK2 antibodies.
FIG. 2. Effect of W13 addition on the duration of ERK2 phos-
phorylation. Quiescent NIH 3T3 cells were preincubated with either
W12 or W13 (15 mg/ml) or without any drug (2) and 20 min later were
stimulated with 10% FBS and harvested at the indicated times (t). Cells
were lysed and ERK2 phosphorylation was analyzed by Western blot
using the antiphospho-ERK1 and ERK2 antibody as indicated under
“Experimental Procedures.” A representative experiment of three dif-
ferent experiments is shown in the figure.
FIG. 3. W13 addition induces ERK2 phosphorylation at low
FBS concentration. A, quiescent (Q) NIH 3T3 cells (0.5% FBS) were
treated for 10 min with 10% FBS or for 30 min with W12 (15 mg/ml),
W13 (15 mg/ml), cyclosporin A (2 mg/ml) (C.A.), or KN93 (5 mM). Then,
cells were lysed and ERK2 phosphorylation was analyzed by Western
blotting using the antiphosphotyrosine (PY20) antibody as indicated
under “Experimental Procedures.” P-ERK2 corresponds to a band of 42
kDa that comigrates with ERK2 using anti-ERK1 and ERK2 antibod-
ies. A representative experiment of three different experiments is
shown in the figure. B, quiescent NIH 3T3 cells were cultured for 10 h
in a media without FBS. Then, W12 (f) or W13 (l ) (15 mg/ml) were
added to the media, and 20 min later, cells were treated for 10 min with
increasing concentrations of FBS. Cells were lysed and ERK2 phospho-
rylation was analyzed by Western blotting using the antiphospho-ERK1
and -ERK2 antibodies as indicated under “Experimental Procedures.”
Bands were quantified by an image analysis system (Bio-Image, Milli-
pore). Values in the graph are the mean of three different experiments;
standard deviations are lower than 10% of the mean.
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Inhibition—The only kinases known to phosphorylate and ac-
tivate ERK2 are MEK1 and MEK2. Thus, we analyzed whether
these kinases were involved in ERK phosphorylation induced
by CaM inhibition. As shown in Fig. 5A, ERK2 phosphorylation
induced by W13 addition to serum-starved cells was not ob-
served when cells were previously treated with the specific
inhibitor of MEK, PD98059 (Calbiochem). Furthermore, W13
addition to serum-starved cells induced an increase in MEK
phosphorylation as determined by Western blotting using
phospho-MEK-specific antibodies (Fig. 5B). These results in-
dicate that W13 induces ERK2 phosphorylation by MEK and
that CaM inhibits the activation of MEK at low serum
concentration.
Next, the effect of CaM inhibition on Raf-1, the main kinase
involved in MEK1 and MEK2 activation, was analyzed. W13
addition to serum-starved cells induced an increase in Raf-1
activity as determined by immunoprecipitation followed by ki-
nase assay using inactive MEK-GST as substrate, compared
with W12-treated cells and quiescent cells (Fig. 6A). CaM in-
hibition induced also a gel-mobility shift of Raf-1, similar to
that induced by FBS (Fig. 6B) that has been related with its
phosphorylation and activation. Although Raf activation is not
very well understood, the increase in Ras-GTP seems to be an
essential event for Raf activation. Thus, the levels of Ras-GTP
upon W13 treatment of serum-starved cells were analyzed. As
shown in Fig. 7A, CaM inhibition induced an increase in the
levels of Ras-GTP that was not observed in W12-treated cells.
The levels of Ras-GTP after W13 treatment were as high as
those reached upon 10% FBS addition. A mechanism for Ras
activation is activation of tyrosine kinase receptors involving
autophosphorylation of these receptors and the recruitment of
SOS to the plasma membrane through the interaction with the
adapter protein GRB2. After 10 min of 10% FBS addition to
serum-starved cells, tyrosine phosphorylation was increased in
the area of the gel where the EGF receptors and PDGF recep-
tors move, 170–190 kDa (Fig. 7B). On the contrary, no increase
in tyrosine phosphorylation in the same area of the gel was
observed after the addition of W13 or W12 to serum-starved
cells (Fig. 7B). Thus, CaM inhibition induced activation of
Ras/Raf/MEK/ERK without any detectable activation of tyro-
sine kinase receptors.
CaM Inhibition Increased the Levels of the Cell Cycle Inhib-
itor p21cip1 and Inhibited Cell Proliferation—In agreement
with previous reports (38) when W13 was added to quiescent
serum-starved NIH 3T3 cells 20 min prior to 10% FBS addition,
DNA synthesis at 20 h was inhibited by 80%. As inhibition of
CaM prevents entry in S phase and prolongs ERK activation,
we looked for a relationship between these two effects. The
expression of p21cip1 has been shown to be dependent on ERK1
and ERK2 activity (20). Thus, the levels of this cell cycle inhib-
itor were analyzed upon CaM inhibition. In W13-pretreated
cells, a prolonged expression of p21cip1 was observed upon FBS
addition (Fig. 8A), being the p21cip1 protein still present 9 h
after serum addition. On the contrary, in control cells (W12-
pretreated cells), 10% FBS addition induced a transient in-
crease in p21cip1 that showed a maximum at 2 h (Fig. 8A).
Thus, inhibition of CaM induced sustained ERK2 activation
FIG. 4. Immunolocalization of ERK2 after W13 addition. Quies-
cent (Q) NIH 3T3 cells were treated with 10% FBS, W12 (15 mg/ml) or
W13 (15 mg/ml) for 30 min. Then cells were fixed with 4% paraformal-
dehyde, and subcellular localization of ERK2 was analyzed by immu-
nocytochemistry using anti-ERK1 and ERK2 antibodies as indicated
under “Experimental Procedures.” FBS and W13 but not W12 induced
the translocation of ERK2 from the cytoplasm into the nucleus.
FIG. 5. MEK is involved in the phosphorylation of ERK in-
duced by W13 addition in serum-starved cells. A, quiescent NIH
3T3 cells (Q) were treated for 10 min with 10% FBS or for 30 min with
W12 or W13 (15 mg/ml). In the indicated lane (W13/PD), cells were
incubated with the MEK inhibitor PD98059 (100 mM) for 30 min prior to
the addition of W13. ERK1 and ERK2 phosphorylation was determined
by Western blotting using antiphospho-ERK1 and -ERK2 antibodies as
indicated under “Experimental Procedures.” B, quiescent NIH 3T3 cells
were activated with 10% FBS for 10 min or treated with W12 or W13 (15
mg/ml) for 30 min. MEK1 and MEK2 phosphorylation was analyzed by
Western blotting using antiphospho-MEK1 and MEK2 specific antibod-
ies as indicated under “Experimental Procedures.” The same blot was
subsequently incubated with antiphospho-ERK1 and ERK2 specific
antibody.
FIG. 6. Effect of W13 addition on Raf activation. A, quiescent
NIH 3T3 cells (Q) were treated for 10 min with 10% FBS or for 30 min
with W12 or W13 (15 mg/ml). Cells were lysed and immunoprecipitated
with anti-Raf antibody (anti-Raf-1) or with a control nonrelated mono-
clonal antibody (mAb) and assayed for kinase activity using MEK-GST
as substrate as indicated under “Experimental Procedures.” A repre-
sentative experiment of a total of three is shown in the figure. B, Raf-1
phosphorylation after CaM inhibition in serum-starved NIH 3T3 cells.
Quiescent NIH 3T3 cells (Q) were treated for 10 min with 10% FBS or
for 30 min with W12 or W13 (15 mg/ml). Cells lysates and Western blot
analysis using anti-raf-1 antibody were done as indicated under “Ex-
perimental Procedures.” The decrease in the electrophoretical mobility
of Raf-1 corresponds to its phosphorylation. The change in electro-
phoretical mobility in FBS-stimulated and W13-treated cells was re-
producible in a total of three experiments.
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and increased p21 expression, in parallel with an inhibition of
cell cycle progression.
CaM inhibition in serum-starved cells (0.5% FBS) also in-
duced the expression of p21cip1 (Fig. 8B). This p21cip1 expres-
sion is MEK-dependent because it was not observed when the
cells were preincubated with the MEK inhibitor PD98059 (100
mM) prior to W13 addition (Fig. 8B).
DISCUSSION
ERK signaling pathway is very important for the cellular
response to extracellular signals. Signaling through this path-
way has been shown to mediate differentiation, proliferation,
or oncogenic transformation depending on the cellular context
and the duration of the activation (19, 58) Thus, in addition to
activation of ERK, its down-regulation is also decisive for cell
response. Inactivation of the pathway is important to prevent
ERK phosphorylation at low serum concentration and to pre-
vent an excessively prolonged peak of ERK activity when cells
are stimulated by growth factors. In this sense, constitutive
and serum-inducible ERK phosphatases have been described,
but inactivation of the pathway upstream of ERK is not well
understood. We have analyzed the involvement of CaM in ERK
activation and inactivation pathways in cell-cultured
fibroblasts.
Ca21 and CaM are essential for the activation of ERK in
response to various stimuli in cortical neurons and lympho-
cytes; however, we have shown here that CaM is not essential
to activate ERK2 by serum, TPA or constitutive activation of
Ras in cultured fibroblasts (NIH 3T3 or NRK cells).These re-
sults agree with the fact that in Rat-1 cells, buffering of Ca21
does not prevent ERK activation induced by LPA or EGF (31).
Thus, although CaM is necessary for NIH 3T3 fibroblast to
reenter cell cycle from quiescence, it is not essential for ERK2
activation.
We have shown that CaM is involved in the down-regulation
of the ERK2 activation pathway. CaM inhibition increases the
duration of ERK2 phosphorylation when cells are stimulated
with 10% FBS. ERK2 activation has a dual effect on cell pro-
liferation. On one hand it induces the expression of cyclin D1
which is essential for G1 progression (59, 60), and on the other
hand it induces p21cip1 expression (20). p21cip1 seems to be
necessary at low levels for cdk4/cyclin D1 activation, but at
high levels acts as an inhibitor of cdk4/cyclin D1 and cdk2/
cyclin E (61, 62). Thus, an intense or highly sustained activa-
tion of ERK2 could induce an excessive increase of p21cip1
expression and, as a consequence, cell cycle inhibition. In fact,
a high intensity Raf signal has recently been shown to cause a
cell cycle arrest mediated by p21cip1 (23, 24). In agreement with
that, the sustained activation of ERK2 induced by CaM inhi-
bition in serum-stimulated cells correlates with a lengthened
expression of p21cip1 and an inhibition of cell proliferation. At
least two reports indicate an inhibitory role of Ca21 on ERK
activity. First, expression of the ERK phosphatase, MKP1, is
Ca21-dependent in Rat-1 cells; consequently, a depletion of the
intracellular Ca21 in these cells induces a more sustained
increase in ERK1 activity (31). Second, Ca21 addition to cul-
tures inhibits EGF-induced stimulation of ERK2 activity in
human primary keratinocytes (63). We have also shown that
CaM inhibition not only leads to a prolonged activation of
ERK2 upon FBS addition but also to an activation of ERK2 at
low serum concentration. The fact that, in total absence of FBS,
CaM inhibition has almost no effect on ERK phosphorylation,
but that a cooperation exists between CaM inhibition and FBS
addition for the activation of ERK2, suggests that CaM inhibits
any of the signal transduction pathways leading to ERK2 phos-
phorylation that are activated by FBS. We have analyzed the
activation of different elements of the ERK signaling pathway
and shown that CaM inhibition leads also to Ras, Raf, and
MEK activation. Thus, we conclude that CaM is down-regulat-
ing the Ras activation pathway, although a multiple effect of
CaM at several levels in the ERK signaling pathway cannot be
excluded. We have also proved that CaM-dependent kinase II
or the CaM-dependent phosphatase calcineurin are not in-
volved in the inhibitory effect of CaM on the ERK activation
pathway.
The rate-limiting step in Ras activation is the exchange of
bound GDP for GTP, which is catalyzed by GEFs (16). Several
guanidine exchange factors are involved in Ras activation in
response to different stimuli. In response to tyrosine kinase
receptors activation, Ras is activated by the SOS nucleotide-
exchange factor. Access of SOS to the membrane where Ras is
located is because of the binding of SOS to the receptor through
SH2 domain- and SH3 domain-mediated interactions involving
FIG. 7. Effect of W13 addition on Ras activation and growth
factor receptor tyrosine phosphorylation. A, quiescent NIH 3T3
cells (Q) were treated for 10 min with 10% FBS or for 30 min with W12
or W13 (15 mg/ml). Cells were lysated and Ras-GTP was determined by
precipitating with RBD-Sepharose followed by Western blotting with
anti-Ras antibody as indicated under “Experimental Procedures.” B,
quiescent NIH 3T3 cells (Q) were treated for 10 min with 10% FCS
(FCS), 25 ng/ml EGF, or for 30 min with W12 or W13 (15 mg/ml). Cells
were lysated and Western blots were performed as indicated under
“Experimental Procedures” using antiphosphotyrosine antibodies
(PY20).
FIG. 8. Effect of W13 addition on p21cip1 expression. A, quiescent
NIH 3T3 cells (Q) were treated with either W12 or W13 (15 mg/ml) and
20 min later were stimulated with 10% FBS. Cells were harvested at
the indicated times after FBS addition. B, quiescent NIH 3T3 cells (Q)
were treated with 10% FBS, W12, or W13 (15 mg/ml) for 2 h. In the
indicated lane (W13/PD), cells were incubated with the MEK inhibitor
PD98059 (100 mM) for 30 min prior to the addition of W13. In both
panels A and B, cells were lysed and p21cip1 levels were analyzed by
Western blotting as indicated under “Experimental Procedures.” Both
panels A and B are representative results of three different
experiments.
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the adapter proteins GRB2 and SHC. Although it has been
shown that some tyrosine kinase receptors such as EGF recep-
tor are able to bind CaM (64, 65) we have not observed any
increase in tyrosine phosphorylation levels of the EGF receptor
or any other protein of 170–190 kDa after CaM inhibition.
Other Ras guanidine exchange factor have been identified as
Ras-GRF/Cdc25Mm (66) and Ras-GRF2 (67). Both factors are
most abundant in brain but are also expressed in other tissues
and a variety of cell lines (66, 68). Activation of these factors is
not very well understood, and they have been suggested to
respond to G protein-coupled receptors (69). Both factors con-
tain IQ motifs that allow their binding to CaM, and in both
neurons and epithelial cells, its activity seems to be stimulated
by Ca21 (47, 67). Those results are controversial because in
vitro studies show that full-length Ras-GRF activity is inhib-
ited by CaM (70). Our results agree with the presence of Ras-
GRF or a homologous protein in NIH 3T3 cells whose activity is
inhibited by CaM. Studies to determine this are underway in
our laboratory. Alternatively CaM could activate a GAP protein
acting on Ras. In this sense, it has been shown that IQGAP1
binds CaM and that its interaction with cdc42 is inhibited by
CaM (71).
We propose two possible physiological roles, which are not
exclusive, for the negative regulation of the ERK signaling
pathway by CaM. First, CaM is defining a threshold in the
Ras/Raf/MEK/ERK signaling pathway to prevent activation of
the pathway at low serum concentration because of the basal
activity of some components of the pathway upstream of Ras.
When growth factor receptors are activated by serum addition,
this threshold is overpassed and ERK is activated even in the
presence of Ca21 and CaM. Second, CaM down-regulation of
Ras is essential to regulate the duration and the intensity of
ERK activation. In consequence, CaM inhibition prolongs Ras/
Raf/MEK/ERK activation and p21cip1 expression, and thus in-
duces inhibition of cell cycle progression.
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58. Traverse, S., Gómez, N., Paterson, H., Marshall, C., and Cohen, P. (1992)
Biochem. J. 288, 351–355
59. Lavoie, J. N., L’Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. (1996)
J. Biol. Chem. 271, 20608–20616
60. Weber, J. D., Raben, D. M., Phillips, P. J., and Baldassare, J. J. (1997)
Biochem. J. 326, 61–68
61. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C.,
Chou, H. S., Fattaey, A., and Harlow, E. (1997) Genes Dev. 11, 847–862
62. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993)
Cell 75, 805–816
63. Medema, J. P., Sark, M. W., Backendorf, C., and Bos, J. L. (1994) Mol. Cell.
Biol. 14, 7078–7085
64. San Jose, E., Benguria, A., Geller, P., and Villalobo, A. (1992) J. Biol. Chem.
267, 15237–15245
65. Martı́n-Nieto, J., and Villalobo, A. (1998) Biochemistry 37, 227–236
66. Cen, H., Papageorge, A. G., Zippel, R., Lowy D. R., and Zhang, K. (1992) EMBO
J. 11, 4007–4015
67. Fam, N. P., Fan, W. T., Wang, Z., Zhang, L. J., Chen, H., and Moran, M. F.
(1997) Mol. Cell. Biol. 17, 1396–1406
68. Guerrero, C., Rojas, J. M., Chedid, M., Esteban, L. M., Zimonjic, D. B.,
Popescu, N. C., Font-de-Mora, J., and Santos, E. (1996) Oncogene 12,
1097–1107
69. Mattingly, R. R., and Macara, I. G. (1996) Nature 382, 268–672
70. Baouz, S., Jacquet, E., Bernardi, A., and Parmeggiani, A. (1997) J. Biol. Chem.
272, 6671–6676
71. Joyal, J. L., Annan, R. S., Ho, Y. D., Huddleston, M. E., Carr, S. A., Hart, M. J.,
and Sacks, D. B. (1997) J. Biol. Chem. 272, 15419–15425
Calmodulin and ERK2 Activation22150
